| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
| Asthenia | D001247 | 5 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Breast Neoplasms | D001943 | 24 associated lipids |
| Lymphoma, B-Cell | D016393 | 24 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Hyperplasia | D006965 | 34 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
| Leukemia, Myeloid | D007951 | 52 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Shen BQ et al. | Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. | 2012 | Nat. Biotechnol. | pmid:22267010 |
| Knobloch T et al. | Mutational biosynthesis of ansamitocin antibiotics: a diversity-oriented approach to exploit biosynthetic flexibility. | 2011 | Chembiochem | pmid:22238146 |
| Li Y et al. | Dual carbamoylations on the polyketide and glycosyl moiety by asm21 result in extended ansamitocin biosynthesis. | 2011 | Chem. Biol. | pmid:22195559 |
| Kang Q et al. | Biosynthesis of 3,5-AHBA-derived natural products. | 2012 | Nat Prod Rep | pmid:22193711 |
| Taft F et al. | Combined muta- and semisynthesis: a powerful synthetic hybrid approach to access target specific antitumor agents based on ansamitocin P3. | 2012 | Chemistry | pmid:22170289 |
| Eichner S et al. | The interplay between mutasynthesis and semisynthesis: generation and evaluation of an ansamitocin library. | 2012 | Angew. Chem. Int. Ed. Engl. | pmid:22135226 |
| Bai RL et al. | Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. | 1990 | J. Biol. Chem. | pmid:2211617 |
| Gurtner K et al. | Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. | 2012 | Radiother Oncol | pmid:22100655 |
| Bertholjotti I | [Antibody-drug conjugate--a new age for personalized cancer treatment]. | 2011 | Chimia (Aarau) | pmid:22026193 |
| Blanc V et al. | SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. | 2011 | Clin. Cancer Res. | pmid:22003072 |
| LoRusso PM et al. | Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. | 2011 | Clin. Cancer Res. | pmid:22003071 |
| Mathew J and Perez EA | Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. | 2011 | Curr Opin Oncol | pmid:21986845 |
| Tuma RS | Enthusiasm for antibody-drug conjugates. | 2011 | J. Natl. Cancer Inst. | pmid:21972230 |
| Gupta M et al. | Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. | 2012 | J Clin Pharmacol | pmid:21953571 |
| Jia Y and Zhong JJ | Enhanced production of ansamitocin P-3 by addition of Mg2+ in fermentation of Actinosynnema pretiosum. | 2011 | Bioresour. Technol. | pmid:21907573 |
| Fishkin N et al. | A novel pathway for maytansinoid release from thioether linked antibody-drug conjugates (ADCs) under oxidative conditions. | 2011 | Chem. Commun. (Camb.) | pmid:21874179 |
| Hinow P et al. | Modeling the effects of drug binding on the dynamic instability of microtubules. | 2011 | Phys Biol | pmid:21836336 |
| Beck A et al. | World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany. | 2011 Jul-Aug | MAbs | pmid:21691144 |
| Wu Y et al. | N-methylation of the amide bond by methyltransferase asm10 in ansamitocin biosynthesis. | 2011 | Chembiochem | pmid:21681880 |
| Olson EM et al. | Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. | 2012 | Ann. Oncol. | pmid:21531783 |